When might I refer a patient?
Our current NGS based test is specifically designed to help guide treatment decisions with targeted therapies (does not include PARP or immune checkpoint inhibitors), which are now widely used in common solid tumours such lung, colorectal, skin, gastric and more recently breast cancers. Not unsurprisingly therefore, the optimal time to refer a case is when such therapies may represent an appropriate treatment option. This is typically directed by cancer staging, which will of course vary by case, with some patients being diagnosed with disease that is aggressive or already metastatic and thus it is important to make sure they get the correct approved therapy from the word go. Alternatively, other patients may be diagnosed early and following other interventions (e.g. surgery), may not progress to a stage where tumour profiling is required for many years, if ever. Finally, there are patients who may have exhausted their standard care options, and in these tumour profiling can allow the possibilities of further ‘off-label’ or clinical trial opportunities to be explored.
Find out more about what our tests can tell you.